LOS ANGELES – Ispire Technology Inc., an innovator in vaping technology and precision dosing, reported results for the fiscal third quarter, which ended March 31, 2024, and filed its quarterly report on Form 10-Q on May 14, 2024.
Fiscal Third Quarter 2024 Financial Results
Revenue increased
24% to $30.0 million as compared to $24.1 million in the same period of 2023. Tobacco vaping products contributed $18.1 million and cannabis vaping products contributed $11.9 million to revenue during the fiscal third quarter 2024;
Gross profit increased 35% to $6.1 million for
the three-month period ended March 31, 2024, compared to $4.5 million in the third quarter of fiscal 2023. Gross profit for the nine-month period ended March 31, 2024, was $19.2 million, compared to $14.3 million for the same period in fiscal 2023.
Gross margin increased to 20.4% as compared
to 18.7% in the same period of 2023;
Total operating expenses increased 63.7%
to $11.8 million as compared to $7.2 million in the same period of 2023; and
Net loss of $5.9 million as compared
to net loss of $2.3 million in the same period of 2023.
Michael Wang, Co-Chief Executive Officer of Ispire, commented,
“The third quarter
was important for Ispire as it demonstrated our continued ability to add new strategic partners and expand within existing market sectors as we execute on our mission to be an innovator and a leader
in our markets. During the quarter, we entered into a joint venture with Berify and Chemulor, and, subsequent to the end of the quarter, announced a partnership with a subsidiary of Acreage Holdings, Inc. (OTCMKTS: ACRGF).
These partnerships will allow us to continue to expand our market share as we offer our cutting-edge products and technology globally.
“Also during the quarter, we successfully closed on a $12.3 million public offering. This additional capital will allow us to help fund our joint
venture with our partners and also ramp up our operations at our Malaysian manufacturing facility. This facility will play an important part in our operational and financial performance as it further streamlines our supply chain which will lead to improved
gross margins and profitability,” concluded Wang.
Daniel Machock, Chief Financial Officer of Ispire, stated, “Our third quarter results reflect Ispire’s ability to capitalize on areas of strength
and to quickly pivot to meet our expectations for our markets. We successfully demonstrated this ability in the third quarter, shifting our focus to increasing profitability due to the anticipated seasonal impact of Chinese New Year on our manufacturing partners.
This ability allowed us to continue to invest in research and innovation, while expanding in our existing markets and ensuring that we were well-positioned to enter new markets where we believe there is significant
market opportunity.”
Financial Results for the Three and Nine-Month Periods Ended March 31, 2024
Revenue increased 24% to $30.0 million for the fiscal third quarter ended March 31, 2024, compared
to $24.1 million in the third quarter of fiscal 2023. The increase in the third quarter of fiscal 2024, was primarily attributable to an increase in North American cannabis vaping hardware sales which increased 57% year-over-year from $7.6 million to $11.9
million.
For the nine-month period ended March 31, 2024, Ispire reported revenue of $114.6 million compared
to $83.0 million during the same period last year, an increase of 38%. The increase in revenue was primarily attributable to an increase in North American cannabis vaping hardware sales which increased 108% from $23.4 million for the first nine-months of fiscal
2023 to $48.8 million for the first nine-months of fiscal 2024.
Gross profit increased by 35% to $6.1 million for the three-month period ended March 31, 2024,
compared to $4.5 million in the third quarter of fiscal 2023. Gross profit for the nine-month period ended March 31, 2024, was $19.2 million compared to $14.3 million for the same period in fiscal 2023.
Gross margin for the three months ended March 31, 2024, was 20.4% compared to 18.7% for the same
period in fiscal 2023. For the nine-month period ended March 31, 2024, gross margin was 16.8%, compared to 17.2% during the same period in the prior fiscal year.
Total operating expenses increased by 64% to $11.8 million for the third quarter in fiscal 2024,
compared to $7.2 million for the same period of fiscal 2023. This increase was primarily due to marketing expenses and working capital related to maintaining our manufacturing plant in Malaysia and increased professional fees for expenses incurred as a public
company. Total operating expenses for the nine-months ended March 31, 2024, were $29.8 million as compared to $17.9 million in the same period in fiscal 2023.
Net loss was $5.9 million or $0.11 per share, for the third quarter of fiscal 2024, compared to
a net loss of $2.3 million, or $0.05 per share for the third quarter of fiscal 2023. For the first nine-months of fiscal 2024, net loss was approximately $11.3 million or $0.21 per share, compared to a net loss of approximately $4.5 million, or $0.09 per share
for the first nine-months of fiscal 2023.
As of March 31, 2024, Ispire had approximately $39.5 million in cash and cash equivalents. As
of March 31, 2024, and June 30, 2023, we had working capital of $28.9 million and $28.8 million respectively.
About Ispire Technology Inc.
Ispire is engaged in the research and development, design, commercialization, sales, marketing, and distribution of branded e-cigarettes and cannabis vaping products. The Company’s operating subsidiaries own or license more than 200 patents received or
filed globally. Ispire’s tobacco products are marketed under the Aspire brand name and are sold worldwide (except in the U.S., People’s Republic of China and Russia) primarily through its global distribution network. The Company’s cannabis products are marketed
under the Ispire brand name primarily on an original design manufacturer (ODM) basis to other cannabis vapor companies. Ispire sells its cannabis vaping hardware only in the U.S., and it recently commenced its marketing activities in
Canada and Europe. Any information contained on, or that can be accessed through, the Company’s website, any other website or any social media, is not a part of this press release.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (“Securities
Act”) as well as Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, as amended, that are intended to be covered by the safe harbor created by those sections. Forward-looking statements,
which are based on certain assumptions and describe the Company’s future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as “believe,” “expect,” “may,” “will,” “should,” “would,” “could,” “seek,” “intend,”
“plan,” “goal,” “project,” “estimate,” “anticipate,” “strategy,” “future,” “likely” or other comparable terms, although not all forward-looking statements contain these identifying words. All statements other than statements of historical facts included in
this press release regarding the Company’s strategies, prospects, financial condition, operations, costs, plans and objectives are forward-looking statements. Important factors that could cause the Company’s actual results and financial condition to differ
materially from those indicated in the forward-looking statements. Such forward-looking statements include, but are not limited to, risks and uncertainties including those regarding: whether the Joint Venture may be successful in achieving its goals as currently
contemplated, with different terms, or at all, the Joint Venture’s ability to innovate in the e-cigarette technology space or develop age gating or age verification technologies for nicotine vaping devices, the Company’s ability to collect its accounts receivable
in a timely manner, the Company’s business strategies, the ability of the Company to market to the Ispire ONE™, Ispire ONE™’s success if meeting its goals, the ability of its customers to derive the anticipated benefits of the Ispire ONE™ and the success of
their products on the markets; the Ispire ONE™ proving to be safe, and the risk and uncertainties described in “Risk Factors,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” “Cautionary Note on Forward-Looking Statements”
and the additional risk described in Ispire’s Annual Report on Form 10-K for the year ended June 30, 2023
and any subsequent filings which Ispire makes with the U.S. Securities and Exchange Commission. You should not rely upon forward-looking statements
as predictions of future events. The forward-looking statements made in the press release relate only to events or information as of the date on which the statements are made in the press release. We undertake no obligation to update or revise any forward-looking
statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events except as required by law. You should read this press release with the understanding
that our actual future results may be materially different from what we expect.
